摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carbaldehyde | 1342469-23-1

中文名称
——
中文别名
——
英文名称
1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carbaldehyde
英文别名
1-(oxan-4-yl)pyrazole-4-carbaldehyde
1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carbaldehyde化学式
CAS
1342469-23-1
化学式
C9H12N2O2
mdl
——
分子量
180.206
InChiKey
CELVSZCQNRDKPN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    44.1
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 储存条件:
    存储条件:2-8℃,氮气保护保存

反应信息

点击查看最新优质反应信息

文献信息

  • CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS
    申请人:C4 Therapeutics, Inc.
    公开号:EP3773576A1
    公开(公告)日:2021-02-17
  • INHIBITORS OF APOL1 AND METHODS OF USING SAME
    申请人:Vertex Pharmaceuticals Incorporated
    公开号:US20220106327A1
    公开(公告)日:2022-04-07
    The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).
  • FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)
    申请人:Merck Patent GmbH
    公开号:US20220389004A1
    公开(公告)日:2022-12-08
    The present invention relates to fused imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
  • [EN] CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS<br/>[FR] LIANTS DE CÉRÉBLON POUR LA DÉGRADATION D'IKAROS
    申请人:C4 THERAPEUTICS INC
    公开号:WO2019191112A1
    公开(公告)日:2019-10-03
    The present invention provides cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications as described herein.
  • WO2019191112A5
    申请人:——
    公开号:WO2019191112A5
    公开(公告)日:2022-03-29
查看更多